Agios Pharmaceuticals Inc (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the first results from the Phase 1 study of AG-120 in patients with IDH1-mutant positive advanced solid tumors will be presented in an oral presentation and featured in the press program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place November 5-9, 2015, in Boston.

“We look forward to sharing the first clinical data for AG-120 in patients with advanced solid tumors as we continue to understand the potential of this investigational medicine,” said Chris Bowden M.D., chief medical officer at Agios. “This is an important step toward our long-term vision of making a difference for people with a broad range of hematologic and solid tumor cancers that harbor IDH mutations.” (Original Source)

Shares of Agios Pharmaceuticals closed today at $64.85, up $3.13 or 5.07%. AGIO has a 1-year high of $138.85 and a 1-year low of $58.62. The stock’s 50-day moving average is $78.36 and its 200-day moving average is $98.93.

On the ratings front, Agios Pharmaceuticals has been the subject of a number of recent research reports. In a report released today, Leerink Swann analyst Seamus Fernandez maintained a Buy rating on AGIO, with a price target of $105, which implies an upside of 61.9% from current levels. Separately, on October 19, Canaccord Genuity’s John Newman maintained a Hold rating on the stock and has a price target of $70.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Seamus Fernandez and John Newman have a total average return of 13.7% and -2.3% respectively. Fernandez has a success rate of 58.8% and is ranked #577 out of 3801 analysts, while Newman has a success rate of 39.3% and is ranked #3322.

Agios Pharmaceuticals Inc is engaged in the development of medicines to treat cancer metabolism and inborn errors of metabolism, which are a subset of orphan genetic metabolic diseases.